[시장보고서]바이오뱅크 시장 - 세계 및 지역별 분석 : 제품 및 서비스, 보관 유형, 샘플 유형, 소유자, 바이오뱅크 유형, 용도, 국가, 지역별 분석과 예측(2025-2035년)

바이오뱅크 시장 - 세계 및 지역별 분석 : 제품 및 서비스, 보관 유형, 샘플 유형, 소유자, 바이오뱅크 유형, 용도, 국가, 지역별 분석과 예측(2025-2035년)

Biobanking Market - A Global and Regional Analysis: Focus on Product and Service, Storage Type, Sample Type, Ownership, Biobank Type, Application, Country, and Region - Analysis and Forecast, 2025-2035

상품코드 : 1811800

리서치사 : BIS Research

발행일 : 2025년 09월

페이지 정보 : 영문

라이선스 & 가격 (부가세 별도)

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

바이오뱅킹 시장의 주요 성장 요인 중 하나는 맞춤형 의료에 대한 수요 증가입니다.

유전체학 및 생명공학의 발전에 따라 환자 개개인의 유전정보를 기반으로 의료를 최적화하려는 움직임이 강화되고 있습니다. 바이오뱅크는 다양한 생물학적 샘플을 보존함으로써 유전적 변이와 그 건강 및 질병에 미치는 영향을 규명하고, 보다 효과적이고 부작용이 적은 표적 치료제 및 치료법을 개발할 수 있게 해줍니다.

또한 암, 당뇨, 심혈관질환 등 만성질환의 증가도 바이오뱅크의 필요성을 높이고 있습니다. 생물학적 물질의 저장소를 제공함으로써 연구자들은 질병 바이오마커를 식별하고, 질병 메커니즘을 이해하고, 새로운 진단 및 치료법을 개발할 수 있습니다. 맞춤형 의료가 현대 의료의 중심축으로 자리 잡으면서 고품질 생물학적 샘플을 제공하는 바이오뱅크에 대한 수요는 지속적으로 확대될 것으로 전망됩니다.

바이오뱅킹 시장이 계속 성장하고 있지만, 몇 가지 과제는 여전히 존재하고 있습니다. 주요 과제 중 하나는 생물학적 샘플의 수집, 보관, 이용에 따른 윤리적, 법적 문제입니다. 사전 동의, 프라이버시, 기증자 정보 기밀 유지 등의 문제는 여전히 큰 과제입니다. 특히 유전정보와 같은 민감한 데이터를 다루는 경우, 시료 제공자가 충분히 이해한 후 동의를 하고, 그 프라이버시가 확실히 보호되는 것이 매우 중요합니다.

또한, 지역이나 기관에 따라 바이오뱅킹에 대한 규제나 표준화가 통일되어 있지 않아 데이터 품질, 시료의 취급, 보관 방식에 차이가 발생하고 있습니다. 이러한 표준화의 부재는 연구기관 간 데이터 공유와 협력을 복잡하게 만들고, 바이오뱅크 자원의 세계 유용성을 제한하는 요인으로 작용하고 있습니다.

마지막으로, 바이오뱅크의 유지에는 재정적, 인프라적 문제가 있습니다. 방대한 데이터와 샘플을 장기간 관리하기 위해서는 보관 시설과 같은 물리적 인프라와 이를 운용하는 기술에 대한 대규모 투자가 필요합니다.

세계 바이오뱅킹 시장에서 가장 중요한 신흥 트렌드 중 하나는 디지털 기술과 자동화의 통합입니다. 이러한 추세는 고급 데이터 관리 시스템, AI 기반 플랫폼, 시료의 수집, 보관, 분석의 자동화 도입과 함께 이루어지고 있습니다. 이러한 기술은 바이오뱅킹 업무의 효율성, 정확성, 확장성을 높이고 대량의 생물학적 샘플을 보다 쉽게 관리할 수 있도록 합니다. 자동화는 프로세스를 간소화하고, 인위적인 오류를 줄이고, 시료 취급의 신뢰성을 높여 시료의 무결성을 유지하는 데 매우 중요한 역할을 합니다.

또한, 디지털 도구는 서로 다른 연구 시설과 지역에 걸쳐 시료의 추적 및 관리를 개선하고, 전 세계 바이오뱅크 네트워크 간의 데이터 공유 및 협력을 보다 효율적으로 촉진합니다. 고품질의 체계적으로 정리된 생물학적 샘플에 대한 수요가 증가함에 따라, 이러한 추세는 앞으로도 바이오뱅킹 산업 형성에 영향을 미쳐 맞춤형 의료, 유전체학, 신약개발의 진전을 뒷받침할 것으로 예상됩니다.

세계의 바이오뱅킹 시장을 조사했으며, 주요 동향, 시장 영향요인 분석, 법·규제 환경, 기술·특허 분석, 시장 규모 추정 및 예측, 각종 부문별·지역별·주요 국가별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

주요 전략과 개발
- M&A
- 상승 효과를 내는 활동
- 사업 확대와 자금 조달
- 제품 발매와 승인
- 기타 활동
기업 개요
- Becton, Dickinson and Company
- QIAGEN N.V.
- Merck KGaA
- Thermo Fisher Scientific Inc.
- PHC Holdings Corporation
- Cryoport, Inc.
- Azenta, Inc.
- Avantor, Inc.
- Tecan Trading AG
- Greiner AG
- Bay Biosciences LLC
- Shanghai Zhangjiang Biobank
- US Biolab Corporation, Inc.
- Cureline
- Brooks Life Sciences

제11장 조사 방법

KSM

영문 목차

영문목차

Global Biobanking Market, Analysis and Forecast: 2025-2035

Biobanking refers to the process of collecting, storing, and managing biological samples (such as blood, tissue, DNA, RNA, and other bodily fluids) for research and medical purposes. These samples are preserved and catalogued in biorepositories or biobanks, where they are stored under controlled conditions to maintain their integrity for long-term use. Biobanks are invaluable resources for scientific research, particularly in fields like genomics, cancer research, drug development, and epidemiology.

Researchers use biobanks to investigate the genetic and environmental factors that contribute to diseases, understand disease mechanisms, and develop personalized treatments. Biobanks are also used for testing the efficacy of new medications, understanding population health trends, and advancing medical knowledge. With the growing focus on precision medicine, biobanks are becoming increasingly important as they provide high-quality biological samples that are essential for creating tailored healthcare solutions based on individual genetic profiles.

One of the key drivers of the biobanking market is the increasing demand for personalized medicine. As advancements in genomics and biotechnology continue to progress, there is a growing focus on tailoring medical treatments to individual patients based on their genetic makeup. Biobanks play a critical role in this area by storing diverse biological samples that can be used to understand genetic variations and their implications on health and disease. These samples help researchers develop targeted therapies and treatments that are more effective and less harmful to patients.

The rise in chronic diseases, such as cancer, diabetes, and cardiovascular conditions, further drives the need for biobanks. By providing a repository of biological materials, biobanks enable researchers to identify disease biomarkers, understand disease mechanisms, and develop new diagnostic and therapeutic methods. As personalized medicine becomes a central pillar of modern healthcare, the demand for biobanks and high-quality biological samples is expected to continue to grow.

Despite the growth of the biobanking market, several challenges persist. One of the primary challenges is the ethical and legal concerns associated with the collection, storage, and use of biological samples. Issues surrounding informed consent, privacy, and confidentiality of donor information remain a significant challenge. Ensuring that individuals provide informed consent for the use of their biological samples in research and that their privacy is protected is crucial, especially when dealing with sensitive genetic data.

Furthermore, the lack of uniform regulations and standardization in biobanking practices across different regions and institutions can lead to discrepancies in data quality, sample handling, and storage methods. This lack of standardization complicates data sharing and collaboration among research institutions, which can limit the global utility of biobank resources.

Lastly, there are financial, and infrastructure challenges related to maintaining biobanks, as they require significant investment in both the physical infrastructure (such as storage facilities) and technology to manage vast amounts of data and biological samples over extended periods.

The global Biobanking market is highly competitive, with major players such as Becton, Dickinson and Company, QIAGEN N.V., Merck KGaA, Thermo Fisher Scientific Inc., PHC Holdings Corporation, Cryoport, Inc., Azenta, Inc., Avantor, Inc., Tecan Trading AG, Greiner AG, Bay Biosciences LLC, Shanghai Zhangjiang Biobank, US Biolab Corporation, Inc., Cureline, and Brooks Life Sciences leading the way. These companies are continuously innovating and expanding their product portfolios to cater to the growing demand for biological sample storage, processing, and management in research, personalized medicine, and drug development.

The competition in the market is driven by advancements in technology, improvements in storage capabilities, and the increasing need for high-quality biological samples for clinical trials, genomic research, and disease study. With significant investments in infrastructure, digitalization, and regulatory compliance, these key players are well-positioned to shape the future of the biobanking market.

Biobanking Market Segmentation:

Segmentation 1: by Product and Service

Equipment
- Storage Equipment
- Sample Analysis Equipment
- Sample Processing Equipment
- Sample Transport Equipment
Consumables
- Storage Consumables
- Analysis Consumables
- Processing Consumables
- Collection Consumables
Services
- Storage Services
- Processing Services
- Transport Services
- Supply Services
Software

Segmentation 2: by Storage Type

Manual Storage
Automated Storage

Segmentation 3: by Sample Type

Blood Products
Human Tissues
Cell Lines
Nucleic Acids
Biological Fluids
Human Waste Products

Segmentation 4: by Ownership

Universities
National/Regional Agencies
Non-Profit Organizations
Private Organizations

Segmentation 5: by Biobank Type

Physical/Real Biobanks
Tissue Biobanks
Population-Based Biobanks
Genetic (DNA/RNA)
Disease-Based Biobanks
Virtual Biobanks

Segmentation 6: by Application

Regenerative Medicine
Life Science Research
Clinical Research

Segmentation 7: by End User

Pharmaceutical & Biotechnology Companies and Cros
Academic And Research Institutes
Hospitals

Segmentation 8: by Region

North America
Europe
Asia-Pacific
Rest of the World

One of the most significant emerging trends in the global biobanking market is the integration of digital technologies and automation. This trend involves the adoption of advanced data management systems, AI-driven platforms, and automation in sample collection, storage, and analysis. These technologies improve the efficiency, accuracy, and scalability of biobanking operations, making it easier to manage large volumes of biological samples. Automation helps streamline processes, reduces human error, and enhances the reliability of sample handling, which is crucial for maintaining sample integrity.

Moreover, digital tools enable better tracking and management of samples across different research facilities and regions, promoting more efficient data sharing and collaboration between global biobank networks. With the growing demand for high-quality and well-organized biological samples, this trend is expected to continue to shape the biobanking industry, supporting advancements in personalized medicine, genomics, and drug development.

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Biobanking Market: Industry Outlook

1.1 Introduction
1.2 Market Trends
1.3 Regulatory Framework
1.4 Case Studies
1.5 Product Benchmarking
1.6 Market Dynamics
- 1.6.1 Impact Analysis
- 1.6.2 Market Drivers
- 1.6.3 Market Challenges
- 1.6.4 Market Opportunities

2. Global Biobanking Market (by Product and Service), ($Billion), 2024-2035

2.1 Equipment
- 2.1.1 Storage Equipment
- 2.1.2 Sample Analysis Equipment
- 2.1.3 Sample Processing Equipment
- 2.1.4 Sample Transport Equipment
2.2 Consumables
- 2.2.1 Storage Consumables
- 2.2.2 Analysis Consumables
- 2.2.3 Processing Consumables
- 2.2.4 Collection Consumables
2.3 Services
- 2.3.1 Storage Services
- 2.3.2 Processing Services
- 2.3.3 Transport Services
- 2.3.4 Supply Services
2.4 Software

3. Global Biobanking Market (by Storage Type), ($Billion), 2024-2035

3.1 Manual Storage
3.2 Automated Storage

4. Global Biobanking Market (by Sample Type), ($Billion), 2024-2035

4.1 Blood Products
4.2 Human Tissues
4.3 Cell Lines
4.4 Nucleic Acids
4.5 Biological Fluids
4.6 Human Waste Products

5. Global Biobanking Market (by Ownership), ($Billion), 2024-2035

5.1 Universities
5.2 National/Regional Agencies
5.3 Non-Profit Organizations
5.4 Private Organizations

6. Global Biobanking Market (by Biobank Type), ($Billion), 2024-2035

6.1 Physical/Real Biobanks
6.2 Tissue Biobanks
6.3 Population-Based Biobanks
6.4 Genetic (DNA/RNA)
6.5 Disease-Based Biobanks
6.6 Virtual Biobanks

7. Global Biobanking Market (by Application), ($Billion), 2024-2035

7.1 Regenerative Medicine
7.2 Life Science Research
7.3 Clinical Research

8. Global Biobanking Market (by End User), ($Billion), 2024-2035

8.1 Pharmaceutical & Biotechnology Companies and Cros
8.2 Academic And Research Institutes
8.3 Hospitals

9. Global Biobanking Market (by Region), ($Billion), 2024-2035

9.1 North America
- 9.1.1 Key Findings
- 9.1.2 Market Dynamics
- 9.1.3 Market Sizing and Forecast
  - 9.1.3.1 North America Biobanking Market, by Country
    - 9.1.3.1.1 U.S.
    - 9.1.3.1.2 Canada
9.2 Europe
- 9.2.1 Key Findings
- 9.2.2 Market Dynamics
- 9.2.3 Market Sizing and Forecast
  - 9.2.3.1 Europe Biobanking Market, by Country
    - 9.2.3.1.1 Germany
    - 9.2.3.1.2 U.K.
    - 9.2.3.1.3 France
    - 9.2.3.1.4 Italy
    - 9.2.3.1.5 Spain
    - 9.2.3.1.6 Rest of the Europe
9.3 Asia Pacific
- 9.3.1 Key Findings
- 9.3.2 Market Dynamics
- 9.3.3 Market Sizing and Forecast
  - 9.3.3.1 Asia Pacific Biobanking Market, by Country
    - 9.3.3.1.1 China
    - 9.3.3.1.2 Japan
    - 9.3.3.1.3 India
    - 9.3.3.1.4 Australia
    - 9.3.3.1.5 Rest of Asia Pacific
9.4 Rest of the World
- 9.4.1 Key Findings
- 9.4.2 Market Dynamics
- 9.4.3 Market Sizing and Forecast

10. Global Biobanking Market: Competitive Landscape and Company Profiles

10.1 Key Strategies and Development
- 10.1.1 Mergers and Acquisitions
- 10.1.2 Synergistic Activities
- 10.1.3 Business Expansions and Funding
- 10.1.4 Product Launches and Approvals
- 10.1.5 Other Activities
10.2 Company Profiles
- 10.2.1 Becton, Dickinson and Company
  - 10.2.1.1 Overview
  - 10.2.1.2 Top Products / Product Portfolio
  - 10.2.1.3 Top Competitors
  - 10.2.1.4 Target Customers/End-Users
  - 10.2.1.5 Key Personnel
  - 10.2.1.6 Analyst View
- 10.2.2 QIAGEN N.V.
  - 10.2.2.1 Overview
  - 10.2.2.2 Top Products / Product Portfolio
  - 10.2.2.3 Top Competitors
  - 10.2.2.4 Target Customers/End-Users
  - 10.2.2.5 Key Personnel
  - 10.2.2.6 Analyst View
- 10.2.3 Merck KGaA
  - 10.2.3.1 Overview
  - 10.2.3.2 Top Products / Product Portfolio
  - 10.2.3.3 Top Competitors
  - 10.2.3.4 Target Customers/End-Users
  - 10.2.3.5 Key Personnel
  - 10.2.3.6 Analyst View
- 10.2.4 Thermo Fisher Scientific Inc.
  - 10.2.4.1 Overview
  - 10.2.4.2 Top Products / Product Portfolio
  - 10.2.4.3 Top Competitors
  - 10.2.4.4 Target Customers/End-Users
  - 10.2.4.5 Key Personnel
  - 10.2.4.6 Analyst View
- 10.2.5 PHC Holdings Corporation
  - 10.2.5.1 Overview
  - 10.2.5.2 Top Products / Product Portfolio
  - 10.2.5.3 Top Competitors
  - 10.2.5.4 Target Customers/End-Users
  - 10.2.5.5 Key Personnel
  - 10.2.5.6 Analyst View
- 10.2.6 Cryoport, Inc.
  - 10.2.6.1 Overview
  - 10.2.6.2 Top Products / Product Portfolio
  - 10.2.6.3 Top Competitors
  - 10.2.6.4 Target Customers/End-Users
  - 10.2.6.5 Key Personnel
  - 10.2.6.6 Analyst View
- 10.2.7 Azenta, Inc.
  - 10.2.7.1 Overview
  - 10.2.7.2 Top Products / Product Portfolio
  - 10.2.7.3 Top Competitors
  - 10.2.7.4 Target Customers/End-Users
  - 10.2.7.5 Key Personnel
  - 10.2.7.6 Analyst View
- 10.2.8 Avantor, Inc.
  - 10.2.8.1 Overview
  - 10.2.8.2 Top Products / Product Portfolio
  - 10.2.8.3 Top Competitors
  - 10.2.8.4 Target Customers/End-Users
  - 10.2.8.5 Key Personnel
  - 10.2.8.6 Analyst View
- 10.2.9 Tecan Trading AG
  - 10.2.9.1 Overview
  - 10.2.9.2 Top Products / Product Portfolio
  - 10.2.9.3 Top Competitors
  - 10.2.9.4 Target Customers/End-Users
  - 10.2.9.5 Key Personnel
  - 10.2.9.6 Analyst View
- 10.2.10 Greiner AG
  - 10.2.10.1 Overview
  - 10.2.10.2 Top Products / Product Portfolio
  - 10.2.10.3 Top Competitors
  - 10.2.10.4 Target Customers/End-Users
  - 10.2.10.5 Key Personnel
  - 10.2.10.6 Analyst View
- 10.2.11 Bay Biosciences LLC
  - 10.2.11.1 Overview
  - 10.2.11.2 Top Products / Product Portfolio
  - 10.2.11.3 Top Competitors
  - 10.2.11.4 Target Customers/End-Users
  - 10.2.11.5 Key Personnel
  - 10.2.11.6 Analyst View
- 10.2.12 Shanghai Zhangjiang Biobank
  - 10.2.12.1 Overview
  - 10.2.12.2 Top Products / Product Portfolio
  - 10.2.12.3 Top Competitors
  - 10.2.12.4 Target Customers/End-Users
  - 10.2.12.5 Key Personnel
  - 10.2.12.6 Analyst View
- 10.2.13 US Biolab Corporation, Inc.
  - 10.2.13.1 Overview
  - 10.2.13.2 Top Products / Product Portfolio
  - 10.2.13.3 Top Competitors
  - 10.2.13.4 Target Customers/End-Users
  - 10.2.13.5 Key Personnel
  - 10.2.13.6 Analyst View
- 10.2.14 Cureline
  - 10.2.14.1 Overview
  - 10.2.14.2 Top Products / Product Portfolio
  - 10.2.14.3 Top Competitors
  - 10.2.14.4 Target Customers/End-Users
  - 10.2.14.5 Key Personnel
  - 10.2.14.6 Analyst View
- 10.2.15 Brooks Life Sciences
  - 10.2.15.1 Overview
  - 10.2.15.2 Top Products / Product Portfolio
  - 10.2.15.3 Top Competitors
  - 10.2.15.4 Target Customers/End-Users
  - 10.2.15.5 Key Personnel
  - 10.2.15.6 Analyst View

한글목차

목차

주요 요약

제1장 세계의 바이오뱅크 시장 : 업계 전망

제2장 세계의 바이오뱅크 시장 : 제품 및 서비스별

제3장 세계의 바이오뱅크 시장 : 보관 유형별

제4장 세계의 바이오뱅크 시장 : 샘플 유형별

제5장 세계의 바이오뱅크 시장 : 소유자별

제6장 세계의 바이오뱅크 시장 : 바이오뱅크 유형별

제7장 세계의 바이오뱅크 시장 : 용도별

제8장 세계의 바이오뱅크 시장 : 최종사용자별

제9장 세계의 바이오뱅크 시장 : 지역별

제10장 세계의 바이오뱅크 시장 : 경쟁 구도·기업 개요